Observational studies have consistently demonstrated that HFPEF accounts for at least 40- 50% of all heart failure patients depending on the population studied, with higher incidences in older populations 1, 3, 4.
This review article will briefly summarise the epidemiology, diagnosis and current treatments available for HFPEF, before discussing potential novel therapies available in the near future. (HFREF), there are potential new drug treatments on the horizon as well as an emerging appreciation of of HFPEF subgroups for which existing heart failure therapies may be effective. Despite the chasm in available treatments compared with heart failure with reduced ejection fraction Despite the significant morbidity associated with HFPEF 2, there have been limited breakthroughs in its management, relying instead on the treatment of co-morbidities and use of diuretics to ease congestion.
Heart failure with preserved ejection fraction (HFPEF) is characterised by normal left ventricular (LV) systolic function and makes up at least half of all cases of chronic heart failure 1.
0 kommentar(er)
